This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The University of Tokyo. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Teruo Inamoto: Innovator in Malignant Mesothelioma Treatment
Introduction
Teruo Inamoto is a distinguished inventor based in Tokyo, Japan. He has made significant contributions to the field of medical research, particularly in the treatment of malignant mesothelioma. His innovative approach has the potential to change the landscape of therapeutic options available for this challenging condition.
Latest Patents
Inamoto holds a patent for a method of treating malignant mesothelioma. This invention involves a therapeutic agent that comprises a substance inhibiting the binding of CD26 to the extracellular matrix. The patent specifically details the use of an siRNA targeting CD26 cDNA or an anti-CD26 antibody. The method of treatment includes administering this substance to patients in need, showcasing a novel approach to combating this aggressive cancer.
Career Highlights
Teruo Inamoto is affiliated with The University of Tokyo, where he conducts his research and development work. His academic background and ongoing research efforts have positioned him as a key figure in the fight against malignant mesothelioma. His dedication to advancing medical science is evident through his innovative patent.
Collaborations
Inamoto has collaborated with notable colleagues in his field, including Chikao Morimoto and Kei Ohnuma. These partnerships have likely contributed to the depth and breadth of his research, enhancing the impact of his work on malignant mesothelioma treatment.
Conclusion
Teruo Inamoto's contributions to the treatment of malignant mesothelioma through his innovative patent highlight the importance of research and collaboration in medical advancements. His work represents a significant step forward in providing new therapeutic options for patients facing this difficult diagnosis.